• Product
• Discontinued muscle painkillers in heavy demand
• by Kim JiEun Aug 3, 2023 05:35am

• Company
• Variable for contract renewal for joint sales
• by Kim, Jin-Gu Aug 3, 2023 05:35am

• Company
• Rise of 4-drug combos in hypertension/hyperlipidemia Tx mkt
• by Kim, Jin-Gu Aug 3, 2023 05:35am

• Policy
• Countdown to the Prime Minister’s Biohealth Committee
• by Lee, Jeong-Hwan Aug 3, 2023 05:35am

• Company
• Rx of Generics for Xarelto doubled in 1 yr
• by Kim, Jin-Gu Aug 2, 2023 05:25am

• Company
• Why HK Inno.N’s sales and operating profit fell
• by Kim, Jin-Gu Aug 2, 2023 05:25am

• Company
• GC Biopharma ends its 2-quarter deficit run
• by Kim, Jin-Gu Aug 2, 2023 05:25am

• Company
• Inrebic, tx for myelofibrosis, has become available in Big5
• by Eo, Yun-Ho Aug 2, 2023 05:25am

• Policy
• MOHW ‘Cannnot defer price cuts made under PVA'
• by Lee, Jeong-Hwan Aug 2, 2023 05:25am

• Company
• Shaperon files Phase II IND for its AD treatment
• by Lee, Seok-Jun Aug 1, 2023 05:33am